Vena Cava Filters in Unstable Elderly Patients With Acute Pulmonary Embolism  by Stein, P.D. & Matta, F.
Abstracts
Gregory L. Moneta, MD, Section EditorFamily Members of Patients with Abdominal Aortic Aneurysms Are at
Increased Risk for Aneurysms: Analysis of 618 Probands and Their
Families from the Liège AAA Family Study
Sakalihasan N, Defraigne JO, Kerstenne MA, et al. Ann Vasc Surg
2014;28:787-97.
Conclusion: Aggregation of AAA in families, particularly among
brothers, provides rational for targeted screening studies in relatives of
patients with AAA.
Summary: Aggregation of AAA in families has been reported since
the 1970’s, with the largest collection of 233 AAA families published in
2003 (Kuivaniemi H et al, J Vasc Surg 2003;37:340-5). Familial clustering
of AAA has also been documented in twin studies (Wahlgren CM et al, J
Vasc Surg 2010;51:3-7). In this study the authors sought to analyze the
results of the Liège AAA Family Study that consists of 618 patients with
unrelated AAA, diagnosed at the University Hospital of Liège. They sought
to answer the following questions: (1) What percentage of patients with
AAA (referred as “AAA probands”) had a positive family history for AAA?
(2) What is the prevalence of AAA among the relatives of AAA probands?
(3) Do familial AAA (FAAA) cases differ from nonfamilial (sporadic) AAA
cases in clinical characteristics? The study consisted of patients with unre-
lated AAA from the period of 1999 and 2012, diagnosed at University
Hospital of Liège Belgium. A detailed family history was obtained from
interviews and recorded using Progeny software. The 618 identiﬁed
patients were divided into 2 study groups; Group I: 296 patients with
AAA (268; 91% men) were followed with computerized tomography com-
bined with positron emission tomography; and Group II: 322 patients
with AAA probands (295; 92% men) whose families were invited to ultra-
sonographic screening. In the initial interviews 62 (10%) of the 618
patients with AAA reported a positive family history for AAA. Ultrasound
screening identiﬁed 24 new AAA’s among 186 relatives ($50 years) of
144 families yielding an AAA prevalence of 13%. The highest prevalence
(25%) was found among brothers. By combining the number of AAA’s
found by ultrasound screening with those diagnosed previously, the
observed lifetime prevalence of AAA was estimated to be 32% in brothers.
The familial AAA cases were more likely to have a ruptured AAA than the
sporadic cases (8% vs 2.4%; P < .0001).
Comment: While we already know there is a genetic component to
AAA etiology, the current data highlights the fact that brothers of AAA
patients are those at highest risk. In fact because of the limitations of inter-
views, the prevalence of AAA among family members and brothers of
patients with AAA may actually be underestimated by this and previous
studies of the genetic component of AAA etiology. Given what appears to
be higher propensity for rupture of familial AAA cases, and the high risk
among brothers, it does seem that the author’s conclusion that targeted
screening of the brothers of patients with AAA is reasonable. In addition,
given the high prevalence among brothers, it seems that the screening for
AAAs in brothers of patients with AAA should not have to wait until the
brother reaches 65 years of age.
Thrombolysis for Pulmonary Embolism and Risk of All-Cause
Mortality, Major Bleeding, and Intracranial Hemorrhage: A
Meta-Analysis
Chatterjee S, Chakraborty A, Weinberg I, et al. JAMA 2014;311:2414-21.
Conclusions: Among patients with pulmonary embolism (PE),
including those who were hemodynamically stable with right ventricular
dysfunction, thrombolytic therapy was associated with lower rates of all-
cause mortality and increased risks of major bleeding and intracranial
hemorrhage.
Summary: It seems logical that thrombolytic therapy may be beneﬁ-
cial in the treatment of some patients with PE. However, to date there has
been no individual study with adequate statistical power to determine
whether thrombolytic therapy is associated with improved survival in com-
parison to conventional anticoagulation. The purpose of the author’s paper
was to perform a meta-analysis to determine the mortality beneﬁts and
bleeding risks associated with thrombolytic therapy compared with1094anticoagulation in acute PE, including the subset of patients hemodynam-
ically stable but with right ventricular dysfunction, so called intermediate-
risk PE. The authors searched PubMed, the Cochrane Library, EMBASE,
EBSCO, Web of Science, and CINAHL databases from their inception
through April 10, 2014. Patients were eligible for inclusion in this
meta-analysis if they were in randomized trials comparing thrombolytic
therapy to standard anticoagulant therapy in PE patients. There were
sixteen trials encompassing 2115 individuals identiﬁed. Eight trials
comprising 1775 patients speciﬁed inclusion of patients with intermedi-
ate-risk PE. The data was independently extracted by two reviewers
and included number of patients, patient characteristics, duration of
follow-up and outcomes. Primary outcomes were all-cause mortality
and major bleeding. Secondary outcomes were risk of recurrent embo-
lism and intracranial hemorrhage (ICH). Peto odds ratio (OR) estimates
and associated 95% CIs were calculated using a ﬁxed-effects model. Use
of thrombolytics was associated with lower all-cause mortality (OR, 0.53;
95% CI, 0.32-0.88; 2.17% [23/1061] vs 3.89% [41/1054] with antico-
agulants. The number needed to treat [NNT] ¼ 59) and greater risks of
major bleeding (OR, 2.73; 95% CI, 1.91-3.91; 9.24% [98/1061] vs
3.42% [36/1054]; number needed to harm [NNH] ¼ 18) and
ICH (OR, 4.63; 95% CI, 1.78-12.04; 1.46% [15/1024] vs 0.19%
[2/1019]; NNH ¼ 78). Major bleeding was not signiﬁcantly increased
in patients 65 years and younger (OR, 1.25; 95% CI, 0.50-3.14).
Thrombolysis was associated with a lower risk of recurrent PE (OR,
0.40; 95% CI, 0.22-0.74; 1.17% [12/1024] vs 3.04% [31/1019];
NNT ¼ 54). In intermediate-risk PE trials, thrombolysis was associated
with lower mortality (OR, 0.48; 95% CI, 0.25-0.92) but more major
bleeding events (OR, 3.19; 95% CI, 2.07-4.92).
Comment: The authors indicate that to the author’s knowledge, this
is the ﬁrst analysis of thrombolysis for treatment of PE that has sufﬁcient
statistical power to detect associations with meaningful mortality reduction,
including hemodynamically stable patients with right ventricular dysfunc-
tion. However, if so, then improvement in mortality must be tempered
by what appears to be signiﬁcantly increased risk of major bleeding and
intracranial hemorrhage with use of thrombolytic therapy for PE, particu-
larly in patients older than 65 years of age.
Vena Cava Filters in Unstable Elderly Patients With Acute Pulmonary
Embolism
Stein PD, Matta F. Am J Med 2014;127:222-5.
Conclusions: Vena cava ﬁlers are associated with a reduced in-hospital,
all-cause case fatality rate in unstable adults with pulmonary embolism (PE),
irrespective of age.
Summary: Data from the Nationwide Inpatient Sample suggest infe-
rior vena cava ﬁlters can be associated with a reduced in-hospital all-cause
fatality rate in unstable patients with acute PE (Stein PD et al, Am J Med
2012;125:478-84). The purpose of this paper was to additionally investigate
whether vena cava ﬁlters are associated with a reduced case fatality rate in
adults of all ages with unstable PE, particularly the elderly.
The authors again utilized the Nationwide Inpatient Sample for their
data. They identiﬁed patients with PE who were unstable (in shock or venti-
lator dependent) from 1999 to 2008 from the Nationwide Inpatient
Sample. There were 21,095 unstable patients with PE who received
thrombolytic therapy. In these patients in-hospital all-cause fatality rate
was lower in every age group who received a vena cava ﬁlter in addition
to thrombolytic therapy (P ¼ .0012 to < .0001). Patients aged
>81 years showed the greatest absolute reduction of case fatality rate
with ﬁlters (19%). Among 50,210 unstable patients who did not receive
thrombolytic therapy, case fatality rate also was lower in every age group
who received a vena cava ﬁlter (all P < .0001). Patients aged $81 years
with vena cava ﬁlters showed the greatest absolute risk reduction of case
fatality rate (27.7%).
Comment: Vena cava ﬁlters remain technology in search of proven
beneﬁt. While administrative databases such as the Nationwide Inpatient
Sample are clearly not perfect, they may provide more useful data then
that from individual case series. This data at least provides some justiﬁcations
for use of vena cava ﬁlters in unstable patients with PE requiring
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unstable so randomized data on use of vena cava ﬁlters in patients with un-
stable PE seems unlikely to happen any time soon. What this data does sug-
gest is that old age at least should not be considered a limiting factor when
considering a vena cava ﬁlter in unstable PE patients. The paper does not
deﬁnitively prove that the ﬁlters are required, but it does suggest that
they do not hurt at least in the short term.
Serious Bleeding Events due to Warfarin and Antibiotic
Co-Prescription in a Cohort of Veterans
Lane MA, Zeringue A, McDonald JR. Am J Med 2014;127:657-63.
Conclusions: Patients on Warfarin who are prescribed certain ‘high-
risk’ antibiotics are at higher risk for serious bleeding events.
Summary: Warfarin has a well-known narrow therapeutic index
requiring frequent laboratory monitoring to prevent life-threatening com-
plications due to under- and over-anticoagulation. There are a wide variety
of factors including genetics, dietary factors, and drug interactions as well as
comorbidities that produce signiﬁcant variability in an individual’s dose
response to waraﬁn. Medications that alter the metabolism of warfarin
by inducing or inhibiting cytochrome P450-2C9, may result in a decrease
or increase in anticoagulant effect. Antibiotics such as trimethoprim/sul-
famethoxazole, metronidazole, ﬂuconazole, ciproﬂoxacin, levoﬂoxacin,
azithromycin, and clarithromycin interact with warfarin via the cyto-
chrome P450-2C9 pathway and also may eliminate vitamin K-producing
bacteria in the intestines to further alter the therapeutic effect of warfarin.
Given these antibiotic interactions with warfarin, the authors performed a
retrospective cohort study of veterans who were prescribed warfarin for
30 days without interruption through the U.S. Department of Veterans
Affairs between October 1, 2002 and September 1, 2008. Antibiotics
considered to be high risk for interaction with warfarin (noted above) as
well as ‘low-risk’ antibiotics such as clindamycin and cephalexin were
tracked in these patients. Risk of bleeding event within 30 days of antibi-
otic exposure was measured using Cox proportional hazards regression,
adjusted for demographic characteristics, comorbid conditions, and
receipt of other medications interacting with warfarin. There were a total
of 22,272 patients who met inclusion criteria, with 14,078 and 8194
receiving high- and low-risk antibiotics respectively. There were 93 and
36 bleeding events in the high- and low-risk groups respectively. Receipt
of a ‘high-risk’ antibiotic (hazard ratio [HR], 1.48; 95% CI, 1.00-2.19)
and azithromycin (HR, 1.93; 95% CI, 1.13-3.30) were associated with
increased risk of bleeding as a primary diagnosis. Other ‘high-risk’ antibi-
otics including ciproﬂoxacin, levoﬂoxacin, azithromycin, and trimetho-
prim/sulfamethoxazole were also associated with serious bleeding as a
primary or secondary diagnosis. International normalized ratio (INR) al-
terations were common; 9.7% of patients prescribed ﬂuconazole had
INR values >6. Patients who had an INR performed within 3-14 days
following antibiotic prescription were at decreased risk of serious bleeding
(HR, 0.61; 95% CI, 0.42-0.88).
Comment: The paper highlights known ‘high-risk’ antibiotics for
interaction with warfarin in that alterations in the INR values are common
among patients who receive such antibiotics. In addition, the fact that INR
evaluation within 3-14 days of antibiotic prescription appeared to reduce the
risk of serious bleeding events among patients receiving warfarin indicates
that monitoring INR shortly after beginning a course of the more ‘high-
risk’ antibiotics, should be routine.
Stroke Incidence and Mortality Trends in US Communities, 1987 to
2011
Koton S, Schneider ALC, Rosamond WD, et al. JAMA 2014;312:259-68.
Conclusions: Stroke incidence and stroke mortality rates have
decreased from 1987 to 2011. Decreases vary across age groups, but are
similar across race and sex, indicating improvements in stroke incidence
and outcome continued to 2011.
Summary: The Atherosclerosis Risk in Communities (ARIC) Study
is a prospective study of 15,792 residents in 4 US communities, who were
aged 45 to 64 years at baseline (1987-1989). The study was designed to
investigate variation in cardiovascular diseases by race, sex, location, and
date (Rosamond WD et al, Stroke 1999; 30:736-43). Information on car-
diovascular risk factors and self-reported race was collected at baseline
through interviews and physical examinations. Follow-up has been with
examinations (1990-1992, 1993-1995, and 1996-1998), annual phone
interviews, and active surveillance of discharges from local hospitals as
well as linkage with the National Death Index through December 31,
2011. In this paper the authors utilized patients from the ARIC cohort
from 1987 to 2011. There were 14,357 participants (282,097 person-years) free of stroke at baseline. Participants were recruited for the purpose
of studying all stroke hospitalizations and deaths, and for collection of
baseline information on cardiovascular risk factors (via interviews and
physical examinations) in 1987-1989. A physician reviewer adjudicated
all possible strokes and classiﬁed them as deﬁnite or probable ischemic
or hemorrhagic events. The main outcome measures for the study were
trends in rates of ﬁrst-ever stroke per 10 years of calendar time, estimated
using Poisson regression incidence rate ratios (IRRs), with subsequent
mortality analyzed using Cox proportional hazards regression models
and hazard ratios overall and by race, sex, and age divided at 65 years.
Among 1051 (7%) participants with incident stroke, there were 929 inci-
dent ischemic strokes and 140 with incident hemorrhagic strokes (18 par-
ticipants had both during the study period). Crude incidence rates were
3.73 (95% CI, 3.51-3.96) per 1000 person-years for ischemic stroke
and 0.49 (95% CI, 0.41-0.57) per 1000 person-years for hemorrhagic
stroke. Stoke incidence decreased over time in both white and black par-
ticipants (age-adjusted IRRs per 10-year period, 0.97; 95% CI, 0.76-1.25;
absolute decrease of 0.09 per 1000 person-years, P ¼ .02 for interaction).
The decrease in incidence was similar by sex of participants. Of patients
with incident stroke, 614 (58%) died through 2011. The mortality rate
was higher for hemorrhagic stroke (68%) than for ischemic stroke
(57%). Overall, mortality after stroke decreased over time from absolute
of 8.09 per 100 strokes after 10 years. The decrease in mortality was
mostly accounted for by the decrease in patients younger than 65 years
at the time of incident stroke (HR, 0.65; 95% CI, 0.46-0.93; absolute
decrease of 14.19 per 100 strokes after 10 years but was similar across
race and sex.
Comment: The data indicate the overall decline in stroke mortality is
a combination of decreases in stroke incidence and mortality from stroke
across age. It is encouraging that the decline in incidence is similar in white
and black participants as well as in men and women. However, on the not so
encouraging side, younger participants in the study had no change in their
stroke incidence. A bright spot for the younger patients was that although
stroke incidence was unchanged in the younger patients, stroke mortality
was decreased.
Effect of Supervised Exercise on Physical Function and Balance in
Patients With Intermittent Claudication
Mockford KA, Gohil RA, Mazari F, et al. BJS 2014;101:356-62.
Conclusions: Supervised exercise programs improve physical function
and balance impairment.
Summary: In patients with intermittent claudication exercise im-
proves walking distances, quality of life, and raises levels of daily activity
thereby reducing functional decline and associated morbidity and mortal-
ity in both mid and long tern (McDermott MM et al, J Am Coll Cardiol
2012;59:1159-67). There is also increasing evidence patients with claudi-
cation have balance impairment, suggesting that if exercise can improve
claudication parameters it may also serve as a mechanism of improving
balance and reducing risk of falls and their associated physical and socio-
economic consequences in patients with intermittent claudication. The
purpose of this study was to determine whether a standard supervised
exercise program (SEP) for patients with intermittent claudication
improved speciﬁc measures of functional performance that included
balance. This was a prospective observational study performed at a single
tertiary vascular center in the UK. Patients with intermittent claudication
(Rutherford grades 1-3) were included in the study. They were assessed
at baseline (before SEP) and at 3, 6, and 12 months afterwards for
markers of lower limb ischemia (treadmill walking distance and ankle
brachial index), physical function (6-min walk, Timed Up and Go test,
and Short Physical Performance Battery (SPPB) score), as well as balance
impairment using computerized dynamic posturography with the Sensory
Organization Test (SOT), and quality of life (VascuQoL and Short
Form 36). There were ﬁfty-one participants who underwent SEP. This
signiﬁcantly improved treadmill walking distance (P ¼ .001). Enrollment
in SEP also resulted in improvements in physical function as determined
by the 6-minute maximum walking distance (P ¼ .006), SPPB score
(P < .001), and some domains of both generic (bodily pain,
P ¼ .025) and disease-speciﬁc (social domain, P ¼ .039) quality of life.
There were also signiﬁcant improvements noted in balance, as deter-
mined by the SOT (P < .001).
Comment: The authors point out that a parallel study assessing
the role of percutaneous transluminal angioplasty for claudication showed
no effect on balance. The additional favorable effect of supervised exercise
on balance in addition to quality of life measures and walking distance
provides additional evidence supporting the position that exercise therapy
along with medical management should be the initial and primary interven-
tions in patients with intermittent claudication.
